(Q46461529)

22 December 2017

title

Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis (English)

1 reference

22 December 2017

1 reference

1 reference

Uri Ladabaum

1

1 reference

22 December 2017

James M Scheiman

series ordinal

2

1 reference

22 December 2017

A Mark Fendrick

series ordinal

3

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

22 December 2017

American Journal of Medicine

published in

1 reference

22 December 2017

volume

114

1 reference

22 December 2017

issue

7

1 reference

22 December 2017

page(s)

546-554

1 reference

22 December 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

A genetic model for colorectal tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

7 January 2021

Colon cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Screening for colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Cost-effectiveness model for colon cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Colorectal cancer screening: clinical guidelines and rationale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Cost-effectiveness of colonoscopy in screening for colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Cost-effectiveness of screening for colorectal cancer in the general population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Chemoprevention of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Chemoprevention of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

The role of cyclooxygenases in inflammation, cancer, and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

The relationship between cyclooxygenase-2 expression and colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Polyps and cancer of the large bowel: a necropsy study in Liverpool

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

The prevalence of polyps of the large intestine in Oslo: an autopsy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Barrett's oesophagus, oesophageal cancer and colon cancer: an explanation of the association and cancer chemopreventive potential of non-steroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

Risk of cardiovascular events associated with selective COX-2 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

The coxib story: some lessons and more questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

COX-2 and colon cancer: potential targets for chemoprevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2803%2900095-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(03)00095-0

1 reference

22 December 2017

PubMed ID

12753878

1 reference

22 December 2017